COVID-19 Booster and IIV Schedule in Immunocompromised Hosts
Recruiting
Phase 2
Interventional Study
COVID 19
Influenza
Rheumatoid Arthritis (RA)
Systemic Lupus Erthematosus
Inflammatory Bowel Disease
Solid Organ Transplant Recipients
Immunocompromised Host
People Living With HIV
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Prevention
- Participants needed
- 660 (estimated)
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this pragmatic embedded open-label, 2 x 2 factorial phase II randomized controlled trial is to evaluate strategies to improve COVID-19 booster and influenza vaccine immunogenicity in people living with immunocompromising conditions (PLIC).
The main questions it aims to answer are:
1. Is co-administration of seasonal inactivated influenza vaccine (IIV) with the most up-to-date recomme…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
\- All participants must meet ALL the following inclusion criteria: i. Adults (≥18 years) ii. Received the primary mRNA COVID-19 vaccine series (i.e., ≥3 doses) iii. Have at least one of the following immunocompromising conditions:
a) Received a solid organ transplant (SOT) ≥3-…
Contacts
Ruth Sapir-Pichhadze, B.Med.Sc, MD, MSc, PhD, FRCPC
5149341934
ruth.sapir-pichhadze.med@ssss.gouv.qc.ca
CONTACT